Mirum Pharmaceuticals, Inc. (MIRM) Quick Ratio
- Quick ratio · latest quarter: Value 2.62×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 2.62× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $583.65M ÷ $222.79M ≈ 2.62× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 583.65M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 222.79M USD | Liabilities, Current |
| Cash and equivalents | 330.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 107.56M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 145.36M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 25.77M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $583.65M | $222.79M | $330.73M | $107.56M | $145.36M | $25.77M | 2.62× |
| 2026-03-31 | $519.37M | $272.82M | $324.91M | $61.35M | $133.11M | $25.52M | 1.90× |
| 2025-12-31 | $506.66M | $205.80M | $296.68M | $86.64M | $123.33M | $24.89M | 2.46× |
| 2025-09-30 | $482.68M | $160.36M | $282.02M | $93.53M | $107.13M | $24.02M | 3.01× |
| 2025-06-30 | $411.39M | $144.80M | $228.12M | $76.43M | $106.84M | $22.94M | 2.84× |
| 2025-03-31 | $373.53M | $127.58M | $211.82M | $65.85M | $95.85M | $22.42M | 2.93× |
| 2024-12-31 | $358.60M | $126.55M | $222.50M | $57.81M | $78.29M | $22.40M | 2.83× |
| 2024-09-30 | $352.98M | $115.75M | $222.97M | $61.48M | $68.53M | $21.59M | 3.05× |
| 2024-06-30 | $338.80M | $112.31M | $233.25M | $45.13M | $60.43M | $20.44M | 3.02× |
| 2024-03-31 | (m) | $105.91M | $302.84M | (m) | $55.00M | $21.61M | (m) |
| 2023-12-31 | (m) | $87.06M | $286.33M | (m) | $67.97M | $22.31M | (m) |
| 2023-09-30 | $353.86M | $74.66M | $303.06M | $2.97M | $47.83M | $22.25M | 4.74× |
| 2023-06-30 | $365.28M | $58.20M | $297.23M | $32.73M | $35.33M | $8.51M | 6.28× |
| 2023-03-31 | $156.73M | $48.84M | $49.42M | $82.65M | $24.66M | $6.61M | 3.21× |
| 2022-12-31 | $175.71M | $64.73M | $28.00M | $123.72M | $23.99M | $5.57M | 2.71× |
| 2022-09-30 | $201.68M | $51.40M | $35.76M | $149.59M | $16.34M | $6.94M | 3.92× |
| 2022-06-30 | $138.94M | $45.17M | $55.27M | $69.69M | $13.99M | $4.52M | 3.08× |
| 2022-03-31 | $147.78M | $34.55M | $46.27M | $93.64M | $7.87M | $1.58M | 4.28× |
| 2021-12-31 | $159.81M | $42.60M | $31.34M | $125.20M | $3.27M | $1.51M | 3.75× |
| 2021-09-30 | (m) | $50.39M | $55.84M | $134.19M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $29.03M | $91.94M | $131.91M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $35.02M | $90.68M | $122.44M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $18.46M | $142.09M | $89.73M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $18.79M | $48.78M | $84.97M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $16.58M | $83.04M | $66.29M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $13.55M | $72.03M | $87.50M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $13.08M | $11.97M | $104.69M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $10.91M | $30.81M | $95.44M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $11.11M | $41.82M | $42.38M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.45M | $51.96M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |